MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...
Plaintiffs opposed Parse’s motions by asserting that: (i) Parse directly infringed the Giresi Patents by using Plaintiffs’ data and protocols in experiments and presentations and indirectly ...
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of ...
Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...
Atea Pharmaceuticals (AVIR) announced the poster presentation of bemnifosbuvir preclinical data at the 38th International Conference on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback